Seizures in low- and high-grade gliomas: Current management and future outlook

Expert Review of Anticancer Therapy

Volumn 10, Issue 5, 2010, Pages 663-669

  Vecht, Charles J ^a   Wilms, Erik B ^a  

^a Medical Center the Hague   (Netherlands)

Author keywords

Anticonvulsant; Chemotherapy; Drug interactions; Epilepsy; Glioblastoma; Gliomas; Levetiracetam; Seizures; Valproic acid

Indexed keywords

ABC TRANSPORTER; ANTICONVULSIVE AGENT; BEVACIZUMAB; CARBAMAZEPINE; CARMUSTINE; CISPLATIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTOCHROME P450; DOXORUBICIN; ETIRACETAM; ETOPOSIDE; IMATINIB; IRINOTECAN; LAMOTRIGINE; LOMUSTINE; METHOTREXATE; PHENOBARBITAL; PHENYTOIN; PRIMIDONE; TAXANE DERIVATIVE; TEMOZOLOMIDE; TOPIRAMATE; VALPROIC ACID; VINCRISTINE;

ADD ON THERAPY; ADJUVANT CHEMOTHERAPY; ANTINEOPLASTIC ACTIVITY; BLOOD BRAIN BARRIER; BRAIN RADIATION; BRAIN TUMOR; CHEMOTHERAPY; CLINICAL PRACTICE; CLINICAL TRIAL; COENZYME; CORTICAL DYSPLASIA; DISEASE CONTROL; DISEASE COURSE; DRUG ACTIVITY; DRUG EFFICACY; DRUG MONITORING; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG TRANSPORT; EPILEPSY; GLIOBLASTOMA; GLIOMA; GRAND MAL SEIZURE; HIPPOCAMPAL SCLEROSIS; HUMAN; MENTAL DETERIORATION; MONOTHERAPY; MULTIDRUG RESISTANCE; NEUROSURGERY; PROPHYLAXIS; REVIEW; SEIZURE; TONIC CLONIC SEIZURE; TOXICITY;

ANIMALS; ANTICONVULSANTS; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; DISEASE MANAGEMENT; DRUG INTERACTIONS; DRUG RESISTANCE, MULTIPLE; FORECASTING; GLIOMA; HUMANS; SEIZURES;

EID: 77952519870     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.10.48     Document Type: Review

References (80)

1. van Veelen ML, Avezaat CJ, Kros JM, van Putten W, Vecht C. Supratentorial low grade astrocytoma: prognostic factors, dedifferentiation, and the issue of early versus late surgery. J. Neurol. Neurosurg. Psychiatry 64, 581-587 (1998).
2. Herman ST. Epilepsy after brain insult: targeting epileptogenesis. Neurology 59, S21-S26 (2002).
3. Pasquier B, Peoc'H M, Fabre-Bocquentin B et al. Surgical pathology of drug-resistant partial epilepsy. A 10-yearexperience with a series of 327 consecutive resections. Epileptic Disord. 4, 99-119 (2002).
4. Lieu AS, Howng SL. Intracranial meningiomas and epilepsy: incidence, prognosis and influencing factors. Epilepsy Res. 38, 45-52 (2000).
5. Naus CC, Bechberger JF, Caveney S, Wilson JX. Expression of gap junction genes in astrocytes and C6 glioma cells. Neurosci. Lett. 126, 33-36 (1991).
6. Haglund MM, Berger MS, Kunkel DD, Franck JE, Ghatan S, Ojemann GA. Changes in γ-aminobutyric acid and somatostatin in epileptic cortex associated with low-grade gliomas. J. Neurosurg. 77, 209-216 (1992).
7. Aronica E, Yankaya B, Jansen GH et al. Ionotropic and metabotropic glutamate receptor protein expression in glioneuronal tumours from patients with intractable epilepsy. Neuropathol. Appl. Neurobiol. 27, 223-237 (2001).
8. Stefan H, Scheler G, Hummel C et al. Magnetoencephalography (MEG) predicts focal epileptogenicity in cavernomas. J. Neurol. Neurosurg. Psychiatry 75, 1309-1313 (2004).
9. Bateman DE, Hardy JA, McDermott JR, Parker DS, Edwardson JA. Amino acid neurotransmitter levels in gliomas and their relationship to the incidence of epilepsy. Neurol. Res. 10, 112-114 (1988).
10. Schaller B. Influences of brain tumourassociated pH changes and hypoxia on epileptogenesis. Acta Neurol. Scand. 111, 75-83 (2005).
11. Beaumont A, Whittle IR. The pathogenesis of tumour associated epilepsy. Acta Neurochir. (Wien) 142, 1-15 (2000).
12. Sirven JI, Wingerchuk DM, Drazkowski JF, Lyons MK, Zimmerman RS. Seizure prophylaxis in patients with brain tumours: a meta-analysis. Mayo Clin. Proc. 79, 1489-1494 (2004).
13. Glantz MJ, Cole BF, Forsyth PA et al. Practice parameter: anticonvulsant prophylaxis in patients with newly diagnosed brain tumours. Report of the Quality Standards Subcommittee of the American Academy of Neurology Neurology 54, 1886-1893 (2000).
14. Wen PY, Marks PW. Medical management of patients with brain tumours. Curr. Opin. Oncol. 14, 299-307 (2002).
15. Patsalos PN, Perucca E. Clinically important drug interactions in epilepsy: interactions between antiepileptic drugs and other drugs. Lancet Neurol. 2, 473-481 (2003). Useful overview of the mechanics of drug interactions illustrated by common clinical examples of interactions of anticonvulsants with other agents. (Pubitemid 36876104)
16. Vecht CJ, Wagner GL, Wilms EB. Interactions between antiepileptic and chemotherapeutic drugs. Lancet Neurol. 2, 404-409 (2003).
17. Yap KY, Chui WK, Chan A. Drug interactions between chemotherapeutic regimens and antiepileptics. Clin. Ther. 30, 1385-1407 (2008). Excellent review on the pharmacokinetics of interactions between anticonvulsants and chemotherapeutic agents in general oncology, and divided per tumor type.
18. Gilbert MR, Supko JG, Batchelor T et al. Phase I clinical and pharmacokinetic study of irinotecan in adults with recurrent malignant glioma. Clin. Cancer Res. 9, 2940-2949 (2003).
19. Bourg V, Lebrun C, Chichmanian RM, Thomas P, Frenay M. Nitrosourea-cisplatin-based chemotherapy associated with valproate: increase of haematologic toxicity. Ann. Oncol. 12, 217-219 (2001).
20. Grossman SA, Sheidler VR, Gilbert MR. Decreased phenytoin levels in patients receiving chemotherapy. Am. J. Med. 87, 505-510 (1989).
21. Neef C, de Voogd-van der Straaten. An interaction between cytostatic and anticonvulsant drugs. Clin. Pharmacol. Ther. 43, 372-375 (1988).
22. Joerger M, Schellens JH, Beijnen JH. Therapeutic drug monitoring of nonanticancer drugs in cancer patients. Methods Find Exp. Clin. Pharmacol. 26, 531-545 (2004).
23. Johannessen SI, Landmark CJ. Value of therapeutic drug monitoring in epilepsy. Expert Rev. Neurother. 8 (6), 929-939 (2008).
24. Norden AD, Young GS, Setayesh K et al. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology 70, 779-787 (2008).
25. Su YW, Chang M-C, Chang MC et al. Treatment-related myelodysplastic syndrome after temozolomide for recurrent high-grade glioma. J. Neurooncol. 71, 315-318 (2005).
26. Acharya S, Bussel JB. Hematologic toxicity of sodium valproate. J. Pediatr. Hematol. Oncol. 22, 62-65 (2000).
27. Ko CH, Kong CK, Tse PW. Valproic acid and thrombocytopenia: cross-sectional study. Hong Kong Med. J. 7, 15-21 (2001).
28. Sisodiya SM, Lin WR, Harding BN, Squier MV, Thom M. Drug resistance in epilepsy: expression of drug resistance proteins in common causes of refractory epilepsy. Brain 125, 22-31 (2002).
29. Calatozzolo C, Gelati M, Ciusani E et al. Expression of drug resistance proteins Pgp, MRP1, MRP3, MRP5 and GST-pi in human glioma. J. Neurooncol. 74, 113-121 (2005).
30. Loscher W, Potschka H. Blood-brain barrier active efflux transporters: ATP-binding cassette gene family. Neuro Rx 2, 86-98 (2005).
31. Loscher W, Potschka H. Role of multidrug transporters in pharmacoresistance to antiepileptic drugs. J. Pharmacol. Exp. Ther. 301, 7-14 (2002).
32. Rogawski MA. Does P-glycoprotein play a role in pharmacoresistance to antiepileptic drugs? Epilepsy Behav. 3, 493-495 (2002).
33. Potschka H, Volk HA, Loscher W. Pharmacoresistance and expression of multidrug transporter P-glycoprotein in kindled rats. Neuroreport 15, 1657-1661 (2004). Excellent review on the underlying mechanisms of multidrug resistance proteins and how these impair drug penetration through the blood-brain barrier.
34. Baltes S, Fedrowitz M, Tortos CL, Potschka H, Loscher W. Valproic acid is not a substrate for P-glycoprotein or multidrug resistance proteins 1 and 2 in a number of in vitro and in vivo transport assays. J. Pharmacol. Exp. Ther. 320, 331-343 (2007).
35. Vecht CJ, van Breemen M. Optimizing therapy of seizures in patients with brain tumours. Neurology 67, S10-S13 (2006).
36. Relling MV, Pui CH, Sandlund JT et al. Adverse effect of anticonvulsants on efficacy of chemotherapy for acute lymphoblastic leukaemia. Lancet 356, 285-290 (2000).
37. Oberndorfer S, Piribauer M, Marosi C, Lahrmann H, Hitzenberger P, Grisold W. P450 enzyme inducing and non-enzyme inducing antiepileptics in glioblastoma patients treated with standard chemotherapy. J. Neurooncol. 72, 255-260 (2005). Original paper on the difference in survival using carbamazepine versus valproic acid in patients with glioblastoma multiforme.
38. Jaeckle KA, Ballman K, Furth A, Buckner JC. Correlation of enzyme-inducing anticonvulsant use with outcome of patients with glioblastoma. Neurology 73, 1207-1213 (2009). Original paper on the difference in survival using enzyme-inducing antiepileptic drugs (EIAEDs) versus non-EIAEDs in patients with glioblastoma multiforme.
39. Motl S, Zhuang Y, Waters CM, Stewart CF. Pharmacokinetic considerations in the treatment of CNS tumours. Clin. Pharmacokinet. 45, 871-903 (2006).
40. Tibussek D, Distelmaier F, Schonberger S, Gobel U, Mayatepek E. Antiepileptic treatment in paediatric oncology - an interdisciplinary challenge. Klin. Padiatr. 218, 340-349 (2006).
41. van Breemen MS, Wilms EB, Vecht CJ. Epilepsy in patients with brain tumours: epidemiology, mechanisms, and management. Lancet Neurol. 6, 421-430 (2007).
42. Mintzer S, Mattson RT. Should enzymeinducing antiepileptic drugs be considered first-line agents? Epilepsia 50 (Suppl. 8), 42-50 (2009).
43. Kurzwelly D, Herrlinger U, Simon M. Seizures in patients with low-grade gliomas - incidence, pathogenesis, surgical management, and pharmacotherapy. Adv. Tech. Stand. Neurosurg 35, 81-111 (2010).
44. Johannessen LC, Patsalos PN. Drug interactions involving the new second- and third-generation antiepileptic drugs. Expert Rev. Neurother. 10, 119-140 (2010).
45. Karceski S Morrell MJ, Carpenter D. Treatment of epilepsy in adults: expert opinion 2005. Epilepsy Behav. 7, S1-S64 (2005). Important original paper on the choice of the most appropriate individual anticonvulsants depending on the type of epilepsy and comorbidity. (Pubitemid 41131320)
46. Brodie MJ, Perucca E, Ryvlin P, Ben Menachem E, Meencke HJ. Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy. Neurology 68, 402-408 (2007).
47. Perucca E Johannessen S, Johannessen SI. The ideal pharmacokinetic properties of an antiepileptic drug: how close does levetiracetam come? Epileptic Disord. 5 (Suppl. 1), S17-S26 (2003).
48. Toering ST, Boer K, de Groot M et al. Expression patterns of synaptic vesicle protein 2A in focal cortical dysplasia and TSC-cortical tubers. Epilepsia 50, 1409-1418 (2009).
49. Kaminski RM, Matagne A, Leclercq K et al. SV2A protein is a broad-spectrum anticonvulsant target, functional correlation between protein binding and seizure protection in models of both partial and generalized epilepsy. Neuropharmacology 54, 715-720 (2008). Important experimental paper on the potential of synergistic activity of levetiracetam in combination with a number of other anticonvulsants.
50. Otoul C, De Smedt H, Stockis A. Lack of pharmacokinetic interaction of levetiracetam on carbamazepine, valproic acid, topiramate, and lamotrigine in children with epilepsy. Epilepsia 48, 2111-2115 (2007).
51. Gidal BE, Baltes E, Otoul C, Perucca E. Effect of levetiracetam on the pharmacokinetics of adjunctive antiepileptic drugs: a pooled analysis of data from randomized clinical trials. Epilepsy Res. 64, 1-11 (2005).
52. Wagner GL, Wilms EB, Van Donselaar CA, Vecht C. Levetiracetam: preliminary experience in patients with primary brain tumours. Seizure 12, 585-586 (2003).
53. van Breemen MS, Rijsman RM, Taphoorn MJ, Walchenbach R, Zwinkels H, Vecht CJ. Efficacy of anti-epileptic drugs in patients with gliomas and seizures. J. Neurol. 256, 1519-1526 (2009).
54. Maschio M Zapata TE. Levetiracetam in brain tumour patients. Epilepsia 46, 105-106 (2005).
55. Newton HB, Goldlust SA, Pearl D. Retrospective analysis of the efficacy and tolerability of levetiracetam in brain tumour patients. J. Neurooncol. 78, 99-102 (2006).
56. Milligan TA, Hurwitz S, Bromfield EB. Efficacy and tolerability of levetiracetam versus phenytoin after supratentorial neurosurgery. Neurology 71, 665-669 (2008).
57. Lim DA, Tarapore P, Chang E et al. Safety and feasibility of switching from phenytoin to levetiracetam monotherapy for glioma-related seizure control following craniotomy: a randomized Phase II pilot study. J. Neurooncol. 93, 349-354 (2009).
58. Zhou B, Zhang Q, Tian L, Xiao J, Stefan H, Zhou D. Effects of levetiracetam as an add-on therapy on cognitive function and quality of life in patients with refractory partial seizures. Epilepsy Behav. 12, 305-310 (2008).
59. Zaccara G, Gangemi PF, Cincotta M. Central nervous system adverse effects of new antiepileptic drugs. A meta-analysis of placebo-controlled studies. Seizure 17, 405-421 (2008).
60. Uges JW, van Huizen MD, Engelsman J et al. Safety and pharmacokinetics of intravenous levetiracetam infusion as add-on in status epilepticus. Epilepsia 50, 415-421 (2009).
61. Marson AG, Williamson PR, Hutton JL, Clough HE, Chadwick DW. Carbamazepine versus valproate monotherapy for epilepsy. Cochrane Database Syst. Rev. CD001030 (2000).
62. Wick W, Menn O, Meisner C et al. Pharmacotherapy of epileptic seizures in glioma patients: who, when, why and how long? Onkologie 28, 391-396 (2005).
63. Gerstner T, Teich M, Bell N et al. Valproate-associated coagulopathies are frequent and variable in children. Epilepsia 47, 1136-1143 (2006).
64. Ward MM, Barbaro NM, Laxer KD, Rampil IJ. Preoperative valproate administration does not increase blood loss during temporal lobectomy. Epilepsia 37, 98-101 (1996).
65. Anderson GD, Lin YX, Berge C, Ojemann GA. Absence of bleeding complications in patients undergoing cortical surgery while receiving valproate treatment. J. Neurosurg. 87, 252-256 (1997).
66. Eyal S, Yagen B, Sobol E, Altschuler Y, Shmuel M, Bialer M. The activity of antiepileptic drugs as histone deacetylase inhibitors. Epilepsia 45, 737-744 (2004).
67. Li XN, Shu Q, Su JM, Perlaky L, Blaney SM, Lau CC. Valproic acid induces growth arrest, apoptosis, and senescence in medulloblastomas by increasing histone hyperacetylation and regulating expression of p21Cip1, CDK4, and CMYC. Mol. Cancer Ther. 4, 1912-1922 (2005).
68. Tang RF, Faussat AM FAU, Majdak PF et al. Valproic acid inhibits proliferation and induces apoptosis in acute myeloid leukemia cells expressing P-gp and MRP1. Leukemia 18, 1246-1251 (2004).
69. Otoul C, Arrigo C, van Rijckevorsel K, French JA. Meta-analysis and indirect comparisons of levetiracetam with other second-generation antiepileptic drugs in partial epilepsy. Clin. Neuropharmacol. 28, 72-78 (2005).
70. Maschio M, Dinapoli L, Zarabla A. Outcome and tolerability of topiramate in brain tumour associated epilepsy. J. Neurooncol. 86, 61-70 (2008).
71. Kaminski RM, Matagne A, Patsalos PN, Klitgaard H. Benefit of combination therapy in epilepsy: a review of the preclinical evidence with levetiracetam. Epilepsia 50, 387-397 (2009).
72. Taphoorn MJ. Neurocognitive sequelae in the treatment of low-grade gliomas. Semin. Oncol. 30, 45-48 (2003).
73. Klein M, Engelberts NH, van der Ploeg HM et al. Epilepsy in low-grade gliomas: the impact on cognitive function and quality of life. Ann. Neurol. 54, 514-520 (2003). Important original paper on the potential of cognitive toxicity of anticonvulsants in patients with low-grade gliomas.
74. Bosma I, Vos MJ, Heimans JJ. The course of neurocognitive functioning in highgrade glioma patients. Neuro. Oncol. 9, 53-62 (2007).
75. Luyken C, Blumcke I, Fimmers R et al. The spectrum of long-term epilepsyassociated tumours: long-term seizure and tumour outcome and neurosurgical aspects. Epilepsia 44, 822-830 (2003). Original paper on the influence of surgical removal of low-grade gliomas on seizure control.
76. Cascino GD. Surgical treatment for epilepsy. Epilepsy Res. 60, 179-186 (2004).
77. Rogers LR, Morris HH, Lupica K. Effect of cranial irradiation on seizure frequency in adults with low-grade astrocytoma and medically intractable epilepsy Neurology 43, 1599-1601 (1993).
78. Chalifoux R, Elisevich K. Effect of ionizing radiation on partial seizures attributable to malignant cerebral tumours. Stereotact. Funct. Neurosurg. 67, 169-182 (1996).
79. Frenay MP, Fontaine D, Vandenbos F, Lebrun C. First-line nitrosourea-based chemotherapy in symptomatic nonresectable supratentorial pure low-grade astrocytomas. Eur. J. Neurol. 12, 685-690 (2005).
80. Pace A, Vidiri A, Galie E et al. Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and radiological response. Ann. Oncol. 14, 1722-1726 (2003).